Sharemaestro Newsreel

Valion Bio (OTC: VBIO) faces going concern risk and Nasdaq bid price warning

Valion Bio, Inc. (OTC: VBIO) has reported significant financial concerns, including a net loss of $13.3 million for the first six months of 2026 and an accumulated deficit of $66.5 million, raising substantial doubt about its ability to continue as a going concern. The …

Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 3.5% in enVVeno Medical Corporation (NVNO) through 24,605 exercisable warrants. This stake represents 24,605 shares of common stock, based on 682,722 shares outstanding as of July …

CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales

Peter Maag, an insider at CareDx (CDNA), has filed to sell 7,000 common shares valued at $317,112.60 through Morgan Stanley Smith Barney LLC. This proposed sale follows several other significant common stock sales by Maag over the past three months, including blocks of 75,653, …

HeartBeam enters $25 million at-the-market equity sales agreement with Titan Partners

HeartBeam Inc. has signed an at-the-market (ATM) equity offering sales agreement with Titan Partners Securities LLC to sell up to $25 million of its common stock. This move comes as the company faces significant cash burn, with levered free cash flow of negative $13.97 …

Form 8K Heartbeam Inc For: 14 August By Investing.com

This article reports that Heartbeam Inc. filed a Form 8K on August 14. The filing is available through Investing.com, which also provides current market data, including stock performance for BEAT, showing a -15.26% change. The content primarily serves as a notice of the filing …

Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a 9.99% beneficial ownership stake in enGene Holdings Inc. (NASDAQ: ENGN). This stake includes both common shares and pre-funded warrants, with the exercise of warrants capped at 9.99% ownership due to …

Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7

Oppenheimer has reiterated its Buy rating for Equillium (EQ.US) and maintained its target price at $7. This indicates continued confidence from the firm in the company's prospects.

Valion Bio, Inc. Q2 2026: Net loss $7.1M, EPS $(2.17) — 10-Q Summary

Valion Bio, Inc. reported a significant widening of its net loss in Q2 2026 to $7.1M, up from $1.93M in Q2 2025, with diluted loss per share at $(2.17). The company recorded no revenue from continuing operations. Despite financial losses, Valion Bio highlighted progress …

Ensign Group (ENSG) Stock Dropped 8.15% After Nursing Home Care Allegations; Law Firm Opens Securities Investigation

The Ensign Group, Inc. (NASDAQ: ENSG) is under investigation by Kaplan Fox & Kilsheimer LLP for potential violations of federal securities laws. This follows a report from Hunterbrook Media alleging systemic patient care failures and data manipulation within Ensign's nursing home operations, which caused …

Ensign Group Slides as Short-seller Report Sparks Investor Concern

Ensign Group's stock slid following the release of a short-seller report from Night Market Research. The report alleges that Ensign uses a "predatory business model" involving asset stripping, which has led to significant financial distress for some of its care facilities. Despite these claims, …

Modular Medical, Inc. Q1 FY2027: Net loss $(6.49M), EPS $(1.19) — 10-Q Summary

Modular Medical, Inc. (MODD) reported a net loss of $(6.49M) for Q1 FY2027, an improvement from the prior year, with diluted loss per share at $(1.19). The company's cash and cash equivalents significantly decreased, leading to a flagged going-concern risk due to liquidity issues. …

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have reported an amended beneficial ownership stake in NeuroPace Inc. (NPCE). The entities collectively own 1,505,125 shares, representing 4.4% of NeuroPace's common stock as of June 30, 2026, and share both voting and dispositive power …

AtriCure (ATRC) Is Up 10.1% After Unveiling 2030 Revenue Goal And Trial-Driven Expansion Plans

AtriCure (ATRC) saw a 10.1% stock increase after announcing a goal of US$1.00 billion in revenue by 2030, driven by its atrial fibrillation, left atrial appendage management, and postsurgical pain-management franchises, alongside new product launches. The company's expansion plans heavily rely on the successful …

Precipio (PRPO) hits record Q2 revenue above $7M and returns to positive Adjusted EBITDA

Precipio, Inc. (PRPO) announced record Q2 2026 revenue exceeding $7 million, driven by continued customer growth and a 21% increase in product revenues from the previous high in Q4 2025. The company also returned to positive Adjusted EBITDA of $0.4 million, compared to a …

Enlivex Ltd. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing by Enlivex Ltd. (NASDAQ: ENLV) on August 14, 2026, which was a Notice of Effectiveness for an F-3 form. The filing was accepted by the SEC EDGAR system on the same day. The article also provides an …

August 2026's Leading Growth Companies With Insider Confidence

The article highlights top growth companies in the United States with high insider ownership, indicating strong internal confidence. It details companies like Webull, Evolus, and Victoria's Secret, providing an overview of their operations, growth forecasts, and recent developments. The piece suggests that high insider …

ETFs Investing in DexCom, Inc. Stocks

This article provides a list of Exchange Traded Funds (ETFs) that hold DexCom, Inc. stocks, sorted by market value. It highlights how these funds can make investing in stocks more accessible and offer diversified opportunities with lower risk. The list includes various ETFs from …

Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake

OrbiMed Advisors LLC and OrbiMed Capital LLC have disclosed a combined 5% ownership stake in Lexeo Therapeutics, Inc. (LXEO). OrbiMed Advisors LLC holds 4.1% of the common stock with shared voting and dispositive power, while OrbiMed Capital LLC holds 1.0% with sole voting and …

Precipio Q2 Revenue Hits Record $7.0 Million, Up 22% Year Over Year

NexGel (NXGL) plans big share authorization boost and reverse split to protect Nasdaq listing

NexGel, Inc. (NXGL) is seeking stockholder approval for two major proposals: increasing authorized common stock from 25 million to up to 150 million shares and implementing a discretionary reverse stock split with a ratio between 1-for-2 and 1-for-20. These actions are intended to ensure …

BeyondSpring Inc. (BYSI) founders disclose 5.29M shares each in 13G/A

Veeva Systems (VEEV) Could Be 24% Undervalued On Eli Lilly Global Vault CRM Rollout

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

Valion Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Adagio Medical Receives Nasdaq Listing Deficiency Notice

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype

Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands

Belite Bio (BLTE) is currently undervalued by 21% according to Simply Wall St. following the FDA's acceptance of its New Drug Application for tinlarebant with Priority Review. Despite a recent one-day dip, the stock has shown strong momentum over the last month and year, …

BeyondSpring (BYSI) posts deeper H1 2026 loss and flags going concern risk

BeyondSpring Inc. (BYSI) reported a consolidated net loss of $12.4 million for the first half of 2026, with an accumulated deficit of $411.4 million and a total shareholders’ deficit of $36.0 million. The company's management has flagged a "going concern" risk due to recurring …

BeyondSpring Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.9% in Inhibikase Therapeutics, Inc. (IKT) through warrants. This stake, totaling 10,320,875 shares, is primarily held by the Master Fund through various pre-funded and common warrants, …

Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A

Perceptive Advisors and its related entities have filed an updated 13D/A, disclosing a 9.1% beneficial ownership in Nautilus Biotechnology, Inc. (NAUT), totaling 11,634,211 shares. This ownership is primarily held by Perceptive Life Sciences Master Fund, Ltd. and C2 Life Sciences LLC, with Perceptive Advisors …

INSPIREMD Q2 2026 Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and More

INSPIREMD (NSPR) is set to release its Q2 2026 earnings on August 17th, with analysts forecasting revenue of $1.41 million and a loss of $0.20 per share. Recent insider trading shows more purchases than sales, while hedge fund activity indicates both increased and decreased …

Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds

Two Seas Capital group, including Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi, has reported a 9.1% beneficial ownership stake in Nektar Therapeutics (NKTR). As of June 30, 2026, they collectively own 3,092,234 shares of common stock through investment funds, …

Canton Strategic Holdings (NASDAQ: CNTN) posts first Canton Network revenue amid sizable Q2 2026 loss

Insider Selling: Becton, Dickinson and Company (NYSE:BDX) CEO Sells $768,120.00 in Stock

Becton, Dickinson and Company's CEO, Thomas Polen, Jr., sold 4,152 shares of BDX stock worth $768,120 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct ownership by 3.63%. This sale occurred as the company's shares rose 0.7% to $183.16, near its 52-week high, …

Edgewise Therapeutics (NASDAQ:EWTX) CEO Kevin Koch Sells 17,971 Shares of Stock